| C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity U Švajger, M Anderluh, M Jeras, N Obermajer Cellular signalling 22 (10), 1397-1405, 2010 | 295 | 2010 |
| Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site T Tomasic, S Katsamakas, Z Hodnik, J Ilaš, M Brvar, T Solmajer, ... Journal of medicinal chemistry 58 (14), 5501-5521, 2015 | 124 | 2015 |
| Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted … A Šmelcerović, K Tomović, Ž Šmelcerović, Ž Petronijević, G Kocić, ... European journal of medicinal chemistry 135, 491-516, 2017 | 108 | 2017 |
| 5‐Benzylidenethiazolidin‐4‐ones as multitarget inhibitors of bacterial Mur ligases T Tomašić, N Zidar, A Kovač, S Turk, M Simčič, D Blanot, ... ChemMedChem: Chemistry Enabling Drug Discovery 5 (2), 286-295, 2010 | 94 | 2010 |
| Synthesis of Novel DC‐SIGN Ligands with an α‐Fucosylamide Anchor G Timpano, G Tabarani, M Anderluh, D Invernizzi, F Vasile, D Potenza, ... ChemBioChem 9 (12), 1921-1930, 2008 | 79 | 2008 |
| Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and … P Štefanič Anderluh, M Anderluh, J Ilaš, J Mravljak, M Sollner Dolenc, ... Journal of medicinal chemistry 48 (9), 3110-3113, 2005 | 77 | 2005 |
| TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions NH Shirole, D Pal, ER Kastenhuber, S Senturk, J Boroda, P Pisterzi, ... Elife 5, e17929, 2016 | 71 | 2016 |
| Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection K Tomovic, J Lazarevic, G Kocic, M Deljanin‐Ilic, M Anderluh, ... Medicinal research reviews 39 (1), 404-422, 2019 | 64 | 2019 |
| Three-component one-pot synthetic route to 2-amino-5-alkylidene-thiazol-4-ones M Anderluh, M Jukič Tetrahedron 65 (1), 344-350, 2009 | 61 | 2009 |
| Design, synthesis and activity evaluation of mannose-based DC-SIGN antagonists N Obermajer, S Sattin, C Colombo, M Bruno, U Švajger, M Anderluh, ... Molecular Diversity 15, 347-360, 2011 | 59 | 2011 |
| Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors M Anderluh, G Kocic, K Tomovic, R Kocic, M Deljanin-Ilic, A Smelcerovic Pharmacology & therapeutics 167, 100-107, 2016 | 57 | 2016 |
| DC-SIGN antagonists, a potential new class of anti-infectives M Anderluh, G Jug, U Svajger, N Obermajer Current medicinal chemistry 19 (7), 992-1007, 2012 | 55 | 2012 |
| Xanthine oxidase inhibitory properties and anti-inflammatory activity of 2-amino-5-alkylidene-thiazol-4-ones Z Smelcerovic, A Veljkovic, G Kocic, D Yancheva, Z Petronijevic, ... Chemico-biological interactions 229, 73-81, 2015 | 52 | 2015 |
| Monovalent and bivalent N-fucosyl amides as high affinity ligands for Pseudomonas aeruginosa PA-IIL lectin M Andreini, M Anderluh, A Audfray, A Bernardi, A Imberty Carbohydrate research 345 (10), 1400-1407, 2010 | 47 | 2010 |
| Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1, 4-benzoxazine-3 (4H)-one scaffold. A systematic study M Anderluh, J Cesar, P Štefanič, D Kikelj, D Janeš, J Murn, K Nadrah, ... European journal of medicinal chemistry 40 (1), 25-49, 2005 | 46 | 2005 |
| Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs) Miniperspective A Kolarič, M Anderluh, N Minovski Journal of medicinal chemistry 63 (11), 5664-5674, 2020 | 45 | 2020 |
| New biologically active epidioxysterols from Stereum hirsutum F Cateni, B Doljak, M Zacchigna, M Anderluh, A Piltaver, G Scialino, ... Bioorganic & medicinal chemistry letters 17 (22), 6330-6334, 2007 | 45 | 2007 |
| Monovalent mannose-based DC-SIGN antagonists: Targeting the hydrophobic groove of the receptor T Tomašić, D Hajšek, U Švajger, J Luzar, N Obermajer, I Petit-Haertlein, ... European Journal of Medicinal Chemistry 75, 308-326, 2014 | 41 | 2014 |
| Thrombin receptor antagonists, recent advances in PAR-1 antagonist development M Anderluh, M Dolenc Current medicinal chemistry 9 (13), 1229-1250, 2002 | 41 | 2002 |
| Recent advances on smart glycoconjugate vaccines in infections and cancer M Anderluh, F Berti, A Bzducha‐Wróbel, F Chiodo, C Colombo, ... The FEBS journal 289 (14), 4251-4303, 2022 | 38 | 2022 |
Tihomir TomasicUniversity of Ljubljana, Faculty of Pharmacyffa.uni-lj.si의 이메일 확인됨
